Brain trauma breakthroughs, predicting dementia and the benefits of birth centres – this week at the Alfred Research Alliance.
A major study by Burnet Institute has provided new evidence about the safety of birth centres.
Monash University – Central Clinical School
Breakthrough in treatment for brain trauma
Monash University scientists have made a major breakthrough in understanding how our immune system response to head trauma leads to ongoing, long-term health problems.
Read more
Landmark Australian study reveals gait is a predictor of dementia
It is estimated that over 436,000 Australians are living with dementia. Globally, a person is diagnosed with dementia every three seconds and there is an urgent need for inexpensive tests that can pick up signs of dementia early.
Read more
Using AI to tackle invasive fungal infections
Detecting and managing invasive fungal disease (IFD) is a growing area of clinical importance in hospitals globally – particularly in an era of rising drug resistance – yet surveillance of these infections has proved challenging.
Read more
Baker Heart and Diabetes Institute
Exposure to chemicals in everyday products linked with increased risk of type 2 diabetes
A new study has found that exposure to chemicals commonly used in everyday products may be associated with an increased risk of type 2 diabetes.
Read more
Heart Foundation grants to drive innovative research
Identifying markers of vascular ageing and those at risk of organ damage, new drug targets for the failing heart, and the efficacy of exercise to prevent heart dysfunction in patients receiving cardio-toxic cancer therapies are among projects funded by the Heart Foundation.
Read more
Burnet Institute
Evidence backs women’s choice on where to have their babies
Healthy women have more than twice the chance of a normal labour and birth in a planned birth centre birth compared to a planned hospital birth, a major Australian study has found.
Read more
Nasal naloxone set for PBS approval
Burnet Institute welcomes reports the Pharmaceutical Benefits Scheme will subsidise a nasal spray form of the anti-opioid drug naloxone.
Read more
Community grant to support hep C testing
Burnet has been awarded a Gilead Sciences ‘COMMIT’ community grant to promote hepatitis C testing and treatment for people who inject drugs.
Read more